Results 1 to 10 of about 90,529 (237)

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation [PDF]

New England Journal of Medicine, 2001
BACKGROUND Despite current treatments, patients who have acute coronary syndromes without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy and safety of the antiplatelet agent clopidogrel when given with aspirin in
Salim Yusuf, Fei-Li Zhao, Shaesta Mehta, Susan Chrolavicius, Gianni Tognoni, Kimberley Fox, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators   +6 more
semanticscholar   +7 more sources

The Role of Clopidogrel in 2020: A Reappraisal

Cardiovascular Therapeutics, 2020
Antiplatelet therapy is the mainstay of treatment and secondary prevention of cardiovascular disease (CVD), including acute coronary syndrome (ACS), transient ischemic attack (TIA) or minor stroke, and peripheral artery disease (PAD).
Giuseppe Patti, Giuseppe Micieli, Claudio Cimminiello, Leonardo Bolognese   +3 more
doaj   +2 more sources

Clopidogrel Resistance in Patients With Stroke Recurrence Under Single or Dual Antiplatelet Treatment

Frontiers in Neurology, 2021
Background: The factors associated with clopidogrel resistance in patients with stroke recurrence receiving single or dual antiplatelet treatment (SAPT or DAPT) may differ.
Hyun Goo Kang, Seung Jae Lee, Sung Hyuk Heo, Dae-il Chang, Bum Joon Kim   +4 more
doaj   +1 more source

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

Clinical pharmacology and therapy, 2022
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition ...
Craig R. Lee, Jasmine A. Luzum, K. Sangkuhl, Roseann S. Gammal, M. Sabatine, C. Stein, D. Kisor, N. Limdi, Yee Ming Lee, S. Scott, J. Hulot, D. Roden, A. Gaedigk, K. Caudle, T. Klein, Julie A. Johnson, A. Shuldiner   +16 more
semanticscholar   +1 more source

Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.

JAMA cardiology, 2022
Importance Clopidogrel monotherapy after short dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) has not yet been fully investigated in patients with acute coronary syndrome (ACS).
Hirotoshi Watanabe, T. Morimoto, M. Natsuaki, Ko Yamamoto, Y. Obayashi, M. Ogita, S. Suwa, T. Isawa, T. Domei, K. Yamaji, Shojiro Tatsushima, Hiroki Watanabe, M. Ohya, H. Tokuyama, T. Tada, H. Sakamoto, Hiroyoshi Mori, Hiroshi Suzuki, Tenjin Nishikura, K. Wakabayashi, K. Hibi, M. Abe, K. Kawai, K. Nakao, K. Ando, K. Tanabe, Y. Ikari, Y. Morino, K. Kadota, Y. Furukawa, Y. Nakagawa, T. Kimura   +31 more
semanticscholar   +1 more source

Comparison of Light Transmission Aggregometry and VerifyNow in Detecting Clopidogrel Resistance and Factors Affecting Clopidogrel Resistance in AMI-EST Patients Undergoing Percutaneous Coronary Intervention: A Cross-Sectional Study

Indonesian Biomedical Journal, 2021
BACKGROUND: Light transmission aggregometry (LTA) and VerifyNow is commonly used to measure platelet responsiveness to clopidogrel. This study aimed to compare the results of LTA and VerifyNow P2Y12 assay for assessing the clopidogrel resistance in ...
Astuti Giantini, Ina Susianti Timan, Erlin Listiyaningsih, Rahajuningsih Dharma, Rianto Setiabudy, Idrus Alwi, Lia Gardenia Partakusuma, Nuri Dyah Indrasari, Alida Roswita Harahap, Siskawati Suparmin, Windy Sahar, Renan Sukmawan   +11 more
doaj   +1 more source

Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. [PDF]

PLoS ONE, 2018
The clinical significance of the laboratory-based phenomenon of clopidogrel hypo-responsiveness and platelet reactivity associated with acute myocardial infarction, despite chronic clopidogrel therapy, is largely unknown.
Ehud Regev, Elad Asher, Paul Fefer, Roy Beigel, Israel Mazin, Shlomi Matetzky, Platelets and Thrombosis in Sheba (PLATIS) - Study Group   +6 more
doaj   +1 more source

Ilaprazole and Clopidogrel Resistance in Acute Stroke Patients

Biomedicines, 2022
Clopidogrel, an antiplatelet agent used for secondary prevention of cerebrovascular diseases, is often taken with proton pump inhibitors (PPIs). Generally, the combined use of clopidogrel and PPIs causes adverse drug–drug interactions.
In Hwan Lim, Seung Jae Lee, Byoung-Soo Shin, Hyun Goo Kang   +3 more
doaj   +1 more source

Mixture of clopidogrel bisulfate and magnesium oxide tablets reduces clopidogrel dose administered through a feeding tube

Journal of Pharmaceutical Health Care and Sciences, 2021
Background In clinical practice, a mixed suspension of clopidogrel bisulfate and magnesium oxide (MgO) tablets is administered frequently via a feeding tube.
Manahito Aoki, Midori Naya, Shiho Arima, Kaori Shinohara, Masahiro Kato, Kiyoshi Shibuya, Masaki Ohtawa, Tohru Nagamitsu, Katsuya Otori   +8 more
doaj   +1 more source

Ticlopidine and Clopidogrel [PDF]

Circulation, 1999
Abstract —The thienopyridines ticlopidine and clopidogrel are inhibitors of platelet function in vivo. Their mode of action has not been defined, but it appears that they require conversion to as yet unidentified metabolites that are noncompetitive antagonists of the platelet ADP receptor. Inhibition
Martin J. Quinn, Desmond J. Fitzgerald
openaire   +2 more sources